Publicacións (21) Publicacións nas que participase algún/ha investigador/a

2017

  1. Assessment of the Clinical Performance of Platelet Concentrates Treated by Pathogen Reduction Technology in Santiago de Compostela

    Transfusion Medicine and Hemotherapy, Vol. 44, Núm. 1, pp. 5-9

  2. Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure

    Biology of Blood and Marrow Transplantation, Vol. 23, Núm. 10, pp. 1631-1640

  3. Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO)

    Annals of Hematology, Vol. 96, Núm. 8, pp. 1323-1330

  4. Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line: A retrospective multinational study

    International Journal of Molecular Sciences, Vol. 18, Núm. 4

  5. Collection, storage, inspection and quality control of platelet concentrates obtained by apheresis: The situation in Spain

    Transfusion and Apheresis Science, Vol. 56, Núm. 3, pp. 357-361

  6. Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in spain

    ClinicoEconomics and Outcomes Research, Vol. 9, pp. 39-47

  7. Donor CTLA-4 Genotype Modulates the Immune Response to Minor Histocompatibility Antigen Mismatches

    Biology of Blood and Marrow Transplantation, Vol. 23, Núm. 12, pp. 2042-2047

  8. EARLY DETECTION OF HEMOGLOBINOPATHIES IN "PREGNANT WOMEN AT RISK"

    HAEMATOLOGICA, Vol. 102, Núm. Supl. 4, pp. 145

  9. Further psychometric validation of the GAH scale: Responsiveness and effect size

    Journal of Geriatric Oncology, Vol. 8, Núm. 3, pp. 211-215

  10. INFECCION NOSOCOMIAL EN LA UNIDAD DE HOSPITALIZACION DE HEMATOLOGIA. ANALISIS DESCRIPTIVO Y FACTORES DE RIESGO

    HAEMATOLOGICA, Vol. 102, Núm. Supl. 4, pp. 252-253

  11. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

    Blood

  12. Molecular and clinical profile of von willebrand disease in Spain (PCM-EVW-ES): Comprehensive genetic analysis by next-generation sequencing of 480 patients

    Haematologica, Vol. 102, Núm. 12, pp. 2005-2014

  13. ORBITAL CHLOROMA AND T(8;21)

    HAEMATOLOGICA, Vol. 102, Núm. Supl. 4, pp. 169

  14. Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis

    European Journal of Haematology, Vol. 98, Núm. 4, pp. 407-414

  15. Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma

    Cancer Medicine, Vol. 6, Núm. 12, pp. 2766-2774

  16. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 8, pp. 2359-2367

  17. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea

    Haematologica, Vol. 102, Núm. 1, pp. 103-109

  18. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group

    British Journal of Haematology, Vol. 178, Núm. 5, pp. 699-708

  19. TRATAMIENTO SEGÚN ESQUEMA R-MINICHOP EN PACIENTES ANCIANOS DIAGNOSTICADOS DE LINFOMA DIFUSO DE CÉLULAS GRANDES B (LBCG): LA EXPERIENCIA EN NUESTRO CENTRO

    HAEMATOLOGICA, Vol. 102, Núm. Supl. 4, pp. 227-228

  20. The mitochondrial inhibitor oligomycin induces an inflammatory response in the rat knee joint

    BMC Musculoskeletal Disorders, Vol. 18, Núm. 1